AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA’s Breakthrough Therapy ...
Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
The last time I spoke about AtaiBeckley (ATAI), it was with a Seeking Alpha article entitled "Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus." With respect to this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results